All In Biotech

Investigational drug · Phase 3

Cenerimod

Also called: ACT-334441

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Erythematosus, Systemic, SLE - Systemic Lupus Erythematosus, Nephritis, Lupus.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

13

Any phase or sponsor naming "Cenerimod"

First trial start

2022

Dec 13, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cenerimod", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lupus Erythematosus, Systemic
  • SLE - Systemic Lupus Erythematosus
  • Nephritis, Lupus

Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Cenerimod" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 22 on PubMed

Also in development for Lupus Erythematosus, Systemic

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • LitifilimabBIIB059Phase 35 trials

    Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic

  • Zola-celBMS-986353, CC-97540Phase 33 trials

    Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis

  • rapcabtagene autoleucelYTB323Phase 28 trials

    Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.